Wordt geladen...
Soluble CD105 is prognostic of disease recurrence in prostate cancer patients
While the overall five-year survival rate for prostate cancer is near 100%, up to 35% of patients will develop recurrent disease. At the time of prostatectomy, prostate specific antigen (PSA) is used to guide primary therapy with the goal of curative intervention. It can be valuable to know when pri...
Bewaard in:
| Gepubliceerd in: | Endocr Relat Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7002242/ https://ncbi.nlm.nih.gov/pubmed/31648185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0370 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|